2022
DOI: 10.3389/fneur.2022.1066040
|View full text |Cite
|
Sign up to set email alerts
|

Case report: A novel variant in SLC25A46 causing sensorimotor polyneuropathy and optic atrophy

Abstract: SLC25A46 is a mitochondrial protein involved in mitochondrial dynamics. Recently, bi-allelic variants have been identified as a pathogenic cause in a spectrum of neurological syndromes. We report a novel homozygous SLC25A46 variant in two siblings, originating from Iraq. Both presented with optic atrophy and varying neurological symptoms. The neurological examination and nerve conduction studies were consistent with sensorimotor polyneuropathy, one having mild polyneuropathy and the other pronounced polyneurop… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3
3

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 9 publications
0
3
0
Order By: Relevance
“…Using whole-exome sequencing, we uncovered a homozygous missense mutation in SLC25A46 , in a patient with the Leigh syndrome, an early-onset, fatal neurodegenerative disorder ( Janer et al, 2016 ). Subsequently, 29 patients from 22 families were reported with biallelic missense mutations in SLC25A46 ( Fig 1A ) in an increasingly broad spectrum of neurological disorders that includes progressive myoclonic ataxia, autosomal recessive cerebellar ataxias, pontocerebellar hypoplasia with spinal muscular atrophy (PCH1), and Parkinson’s disease and optic atrophy ( Charlesworth et al, 2016 ; Wan et al, 2016 ; Hammer et al, 2017 ; Nguyen et al, 2017 ; Sulaiman et al, 2017 ; van Dijk et al, 2017 ; Abrams et al, 2018 ; Braunisch et al, 2018 ; Bitetto et al, 2020 ; Ababneh et al, 2021 ; Kodal et al, 2022 ). The onset and course of the disease are highly variable, ranging from fetal death to survival to 50 yr of age.…”
Section: Introductionmentioning
confidence: 99%
“…Using whole-exome sequencing, we uncovered a homozygous missense mutation in SLC25A46 , in a patient with the Leigh syndrome, an early-onset, fatal neurodegenerative disorder ( Janer et al, 2016 ). Subsequently, 29 patients from 22 families were reported with biallelic missense mutations in SLC25A46 ( Fig 1A ) in an increasingly broad spectrum of neurological disorders that includes progressive myoclonic ataxia, autosomal recessive cerebellar ataxias, pontocerebellar hypoplasia with spinal muscular atrophy (PCH1), and Parkinson’s disease and optic atrophy ( Charlesworth et al, 2016 ; Wan et al, 2016 ; Hammer et al, 2017 ; Nguyen et al, 2017 ; Sulaiman et al, 2017 ; van Dijk et al, 2017 ; Abrams et al, 2018 ; Braunisch et al, 2018 ; Bitetto et al, 2020 ; Ababneh et al, 2021 ; Kodal et al, 2022 ). The onset and course of the disease are highly variable, ranging from fetal death to survival to 50 yr of age.…”
Section: Introductionmentioning
confidence: 99%
“…Autosomal-dominant mutations in RAB7 lead to Charcot-Marie-Tooth (CMT) type 2B (Meggouh et al 2006) while mutations of MFN2 cause CMT type 2A. SLC25A46 has also been associated with CMT type 2 and a variety of other neurological disorders, such as optic atrophy and cerebellar atrophy (Abrams et al 2018; Abrams et al 2015; Braunisch et al 2018; Buglo et al 2020; Charlesworth et al 2016; Hammer et al 2017; Kodal et al 2022). SLC25A46 is a mitochondrial outer membrane protein (Abrams et al 2015; Janer et al 2016) and plays an ill- defined role in mitochondrial fusion and fission, interacting with the fusion associated proteins MFN2 and OPA1, while the knock-out of SLC25A46 leads to altered oligomerization states of MFN2 and OPA1 (Schuettpelz et al 2023).…”
Section: Introductionmentioning
confidence: 99%
“…A population-based phasing strategy leverages the information of co-occurrences of variants across multiple hundreds to thousands of individuals 13 . Thus, while this strategy can easily phase entire chromosome arms, it can only do so on common SNPs in the population, and therefore misses the rare and likely disease-causing variants 14 , 15 . Another strategy, trio-phasing, involves obtaining parental information and using it to phase a single nucleotide variant (SNV) based on the co-occurrence of the parents 16 .…”
Section: Introductionmentioning
confidence: 99%